OCGN Earnings

OCGN reported its earnings on 2026-03-04, showcasing a revenue of -193.00K against an estimate of 1.50M, resulting in a -112.87% surprise. The EPS was -0.06, surpassing the expected -0.06 by 0%. The stock experienced a 5.38% price change on the earnings day and a -10.75% change over the next five days, reflecting market reactions to the results.

Following OCGN's earnings announcement on 2026-03-04, the stock price moved by 5.38% on the day of the release. Over the subsequent five days, it saw a -10.75% change. Historically, OCGN's stock price tends to shift by an average of 2.64% in the 10 days leading up to earnings and 2.46% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate OCGN's annual revenue to reach 860.00K, while the EPS is projected at -0.06. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OCGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OCGN's stock price typically moves by 2.64% in the 10 days before its earnings and 2.46% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.06 and revenue of 860.00K.

The earnings call presents a mixed picture: while there's optimism in product development and business updates, with management confident in timelines and strategic positioning, financial metrics show increased R&D expenses and net losses. The Q&A section reveals management's confidence but also highlights uncertainties, particularly around FDA feedback and dose selection. The lack of a new partnership or significant shareholder return plan, coupled with increased expenses, suggests a neutral stock movement. Without market cap data, the reaction is assumed to be moderate.